NASDAQ:STML - Stemline Therapeutics News Headlines

$13.00
+0.39 (+3.09 %)
(As of 07/16/2019 04:00 PM ET)
Today's Range
$12.62
Now: $13.00
$13.06
50-Day Range
$12.67
MA: $14.31
$15.92
52-Week Range
$7.82
Now: $13.00
$17.85
Volume497,752 shs
Average Volume604,100 shs
Market Capitalization$567.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Headlines

Stemline Therapeutics (NASDAQ STML) News Headlines

Source:
DateHeadline
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder MeetingStemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting
finance.yahoo.com - July 8 at 6:19 PM
Stemline Therapeutics Inc (NASDAQ:STML) Given Average Recommendation of "Buy" by BrokeragesStemline Therapeutics Inc (NASDAQ:STML) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 2:30 AM
$7.92 Million in Sales Expected for Stemline Therapeutics Inc (NASDAQ:STML) This Quarter$7.92 Million in Sales Expected for Stemline Therapeutics Inc (NASDAQ:STML) This Quarter
www.americanbankingnews.com - June 30 at 3:26 AM
Ivan Bergstein Sells 56,316 Shares of Stemline Therapeutics Inc (NASDAQ:STML) StockIvan Bergstein Sells 56,316 Shares of Stemline Therapeutics Inc (NASDAQ:STML) Stock
www.americanbankingnews.com - June 28 at 8:33 PM
Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman Sells 9,107 SharesStemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman Sells 9,107 Shares
www.americanbankingnews.com - June 28 at 8:33 PM
Ivan Bergstein Sells 10,822 Shares of Stemline Therapeutics Inc (NASDAQ:STML) StockIvan Bergstein Sells 10,822 Shares of Stemline Therapeutics Inc (NASDAQ:STML) Stock
www.americanbankingnews.com - June 28 at 8:33 PM
Kenneth Hoberman Sells 47,115 Shares of Stemline Therapeutics Inc (NASDAQ:STML) StockKenneth Hoberman Sells 47,115 Shares of Stemline Therapeutics Inc (NASDAQ:STML) Stock
www.americanbankingnews.com - June 28 at 8:33 PM
 Analysts Expect Stemline Therapeutics Inc (NASDAQ:STML) to Post -$0.49 Earnings Per Share Analysts Expect Stemline Therapeutics Inc (NASDAQ:STML) to Post -$0.49 Earnings Per Share
www.americanbankingnews.com - June 28 at 10:18 AM
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Stemline Therapeutics, Inc. Common Stock -- STMLThe Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Stemline Therapeutics, Inc. Common Stock -- STML
finance.yahoo.com - June 28 at 8:52 AM
Hedge Funds Have Never Been This Bullish On Stemline Therapeutics Inc (STML)Hedge Funds Have Never Been This Bullish On Stemline Therapeutics Inc (STML)
finance.yahoo.com - June 19 at 7:15 PM
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in SystemicStemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic
www.nasdaq.com - June 17 at 9:25 AM
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR CongressStemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
finance.yahoo.com - June 17 at 9:25 AM
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15
finance.yahoo.com - June 13 at 8:27 AM
Stemline Therapeutics: Updating The Investment ThesisStemline Therapeutics: Updating The Investment Thesis
seekingalpha.com - June 3 at 6:29 PM
When Will Stemline Therapeutics, Inc. (NASDAQ:STML) Turn A Profit?When Will Stemline Therapeutics, Inc. (NASDAQ:STML) Turn A Profit?
finance.yahoo.com - June 3 at 6:29 PM
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML ProgramStemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program
finance.yahoo.com - June 3 at 8:45 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual CongressStemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress
finance.yahoo.com - May 20 at 9:57 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual MeetingStemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting
finance.yahoo.com - May 16 at 10:12 AM
Wedbush: Trajectory For Stemline Therapeutics Blood Cancer Drug Priced Into StockWedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock
finance.yahoo.com - May 13 at 7:31 PM
Stemline Therapeutics (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call TranscriptStemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 8:54 AM
Stemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call TranscriptStemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 11 at 8:54 AM
Edited Transcript of STML earnings conference call or presentation 10-May-19 12:00pm GMTEdited Transcript of STML earnings conference call or presentation 10-May-19 12:00pm GMT
finance.yahoo.com - May 11 at 8:54 AM
Stemline Therapeutics, Inc.  (STML) Q1 2019 Earnings Call TranscriptStemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call Transcript
www.fool.com - May 10 at 6:52 PM
Stemline Therapeutics Reports First Quarter 2019 Financial ResultsStemline Therapeutics Reports First Quarter 2019 Financial Results
www.globenewswire.com - May 10 at 8:55 AM
Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue EstimatesStemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 10 at 8:55 AM
Stemline Therapeutics misses by $0.07, beats on revenueStemline Therapeutics misses by $0.07, beats on revenue
seekingalpha.com - May 10 at 6:40 AM
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019
finance.yahoo.com - May 8 at 8:51 AM
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study ResultsStemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results
finance.yahoo.com - April 25 at 8:44 AM
Announcing: Stemline Therapeutics (NASDAQ:STML) Stock Increased An Energizing 150% In The Last Three YearsAnnouncing: Stemline Therapeutics (NASDAQ:STML) Stock Increased An Energizing 150% In The Last Three Years
finance.yahoo.com - April 23 at 6:01 PM
Stemline Therapeutics Has The Big MoStemline Therapeutics Has The 'Big Mo'
seekingalpha.com - March 18 at 7:22 PM
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH ConferenceStemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference
feeds.benzinga.com - March 18 at 7:50 AM
Stemline Therapeutics Reports Fourth Quarter 2018 Financial ResultsStemline Therapeutics Reports Fourth Quarter 2018 Financial Results
finance.yahoo.com - March 15 at 7:01 PM
Stemline Therapeutics: 4Q Earnings SnapshotStemline Therapeutics: 4Q Earnings Snapshot
finance.yahoo.com - March 15 at 7:01 PM
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology PipelineStemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline
finance.yahoo.com - March 11 at 11:14 AM
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care ConferenceStemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:02 AM
Is Stemline Therapeutics, Inc. (NASDAQ:STML) Excessively Paying Its CEO?Is Stemline Therapeutics, Inc. (NASDAQ:STML) Excessively Paying Its CEO?
finance.yahoo.com - February 19 at 6:37 PM
EMA accepts Stemlines Elzonris marketing application; shares up 2%EMA accepts Stemline's Elzonris marketing application; shares up 2%
seekingalpha.com - January 30 at 6:38 PM
Whats Making News At Roche, EYEN, STML, Sirona, TRVN? - NasdaqWhat's Making News At Roche, EYEN, STML, Sirona, TRVN? - Nasdaq
www.nasdaq.com - January 30 at 8:49 AM
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) - GlobeNewswireStemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) - GlobeNewswire
globenewswire.com - January 30 at 8:49 AM
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
finance.yahoo.com - January 30 at 8:49 AM
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications - NasdaqConsolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications - Nasdaq
www.nasdaq.com - January 25 at 5:46 PM
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications - GlobeNewswireConsolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications - GlobeNewswire
globenewswire.com - January 25 at 8:45 AM
Read This Before Buying Stemline Therapeutics, Inc. (NASDAQ:STML) SharesRead This Before Buying Stemline Therapeutics, Inc. (NASDAQ:STML) Shares
finance.yahoo.com - January 21 at 5:37 PM
Stemline therapeutics closes $92M public offering of common stockStemline therapeutics closes $92M public offering of common stock
seekingalpha.com - January 18 at 9:40 PM
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock - GlobeNewswireStemline Therapeutics Closes $92 Million Public Offering of Common Stock - GlobeNewswire
globenewswire.com - January 18 at 4:40 PM
Stemline Therapeutics Closes $92 Million Public Offering of Common StockStemline Therapeutics Closes $92 Million Public Offering of Common Stock
finance.yahoo.com - January 18 at 4:40 PM
Stemline Therapeutics announces upsizing and pricing of $80M equity offering, shares down 4% premarketStemline Therapeutics announces upsizing and pricing of $80M equity offering, shares down 4% premarket
seekingalpha.com - January 16 at 5:34 PM
Stemline prices stock offering; shares down 4% premarketStemline prices stock offering; shares down 4% premarket
seekingalpha.com - January 16 at 8:49 AM
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% HigherStemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
www.zacks.com - January 16 at 8:49 AM
Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common StockStemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock
finance.yahoo.com - January 16 at 8:49 AM
This page was last updated on 7/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel